Why is the study being conducted?

PREMIER is a large phase II clinical trial being conducted in up to 45 study sites across the United States. Its primary goal is to assess whether a regimen with both sargramostim and rituximab is more effective than rituximab alone. PREMIER is also looking at the safety of the regimen.

The drug (sargramostim) will be supplied to you at no cost. Other treatment costs are generally part of normal cancer care and will be billed to your insurance company. Expenses not covered by your insurance or Medicare may be billed to you.

Your participation in this study is entirely voluntary. If you want to participate, or have any additional questions, please speak to your doctor.